Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:500 - 1:2000 |
1:50 - 1:200 |
1:50 - 1:200 |
Not tested in other applications.
Calculated MW
Observed MW
95 kDa. The observed M.W. is based on the following publication. PMID: 16024601
Form
Liquid
Buffer
PBS, 0.05% BSA, 50% Glycerol
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.24 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
A synthesized peptide derived from human RALBP1.
Purification
Purified by affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
ralA binding protein 1 , RIP1 , RLIP1 , RLIP76
Cellular Localization
Membrane
Background
RALBP1 plays a role in receptor-mediated endocytosis and is a downstream effector of the small GTP-binding protein RAL (see RALA; MIM 179550). Small G proteins, such as RAL, have GDP-bound inactive and GTP-bound active forms, which shift from the inactive to the active state through the action of RALGDS (MIM 601619), which in turn is activated by RAS (see HRAS; MIM 190020) (summary by Feig, 2003 [PubMed 12888294]).[supplied by OMIM, Nov 2010]
Database
Research Area